96 related articles for article (PubMed ID: 12685833)
1. Clinical outcomes associated with very late relapses in diffuse large cell lymphoma.
Ko AH; Yuen AR
Leuk Lymphoma; 2002 Sep; 43(9):1789-93. PubMed ID: 12685833
[TBL] [Abstract][Full Text] [Related]
2. Late relapse in patients with diffuse large-cell lymphoma treated with MACOP-B.
Lee AY; Connors JM; Klimo P; O'Reilly SE; Gascoyne RD
J Clin Oncol; 1997 May; 15(5):1745-53. PubMed ID: 9164181
[TBL] [Abstract][Full Text] [Related]
3. [Efficacy of rituximab-containing salvage regimens on relapsed or refractory B-cell non-Hodgkin's lymphoma].
Huang HQ; Bu Q; Xia ZJ; Lin XB; Wang FH; Li YH; Peng YL; Pan ZH; Wang SS; Lin TY; Jiang WQ; Guan ZZ
Ai Zheng; 2006 Apr; 25(4):486-9. PubMed ID: 16613686
[TBL] [Abstract][Full Text] [Related]
4. Lymphoma recurrence 5 years or later following diffuse large B-cell lymphoma: clinical characteristics and outcome.
Larouche JF; Berger F; Chassagne-Clément C; Ffrench M; Callet-Bauchu E; Sebban C; Ghesquières H; Broussais-Guillaumot F; Salles G; Coiffier B
J Clin Oncol; 2010 Apr; 28(12):2094-100. PubMed ID: 20308668
[TBL] [Abstract][Full Text] [Related]
5. Autologous transplantation for diffuse aggressive non-Hodgkin lymphoma in first relapse or second remission.
Vose JM; Rizzo DJ; Tao-Wu J; Armitage JO; Bashey A; Burns LJ; Christiansen NP; Freytes CO; Gale RP; Gibson J; Giralt SA; Herzig RH; Lemaistre CF; McCarthy PL; Nimer SD; Petersen FB; Schenkein DP; Wiernik PH; Wiley JM; Loberiza FR; Lazarus HM; van Biesen K; Horowitz MM
Biol Blood Marrow Transplant; 2004 Feb; 10(2):116-27. PubMed ID: 14750077
[TBL] [Abstract][Full Text] [Related]
6. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
Hagemeister FB
Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
[TBL] [Abstract][Full Text] [Related]
7. Ifosfamide, epirubicin and etoposide (IEV) regimen as salvage and mobilization therapy for refractory or early relapsing patients with aggressive non-Hodgkin's lymphoma.
Pocali B; De Simone M; Annunziata M; Palmieri S; D'Amico MR; Copia C; Viola A; Mele G; Schiavone EM; Ferrara F
Leuk Lymphoma; 2004 Aug; 45(8):1605-9. PubMed ID: 15370212
[TBL] [Abstract][Full Text] [Related]
8. The International Prognostic Index assessed at relapse predicts outcomes of autologous transplantation for diffuse large-cell non-Hodgkin's lymphoma in second complete or partial remission.
Lerner RE; Thomas W; Defor TE; Weisdorf DJ; Burns LJ
Biol Blood Marrow Transplant; 2007 Apr; 13(4):486-92. PubMed ID: 17382255
[TBL] [Abstract][Full Text] [Related]
9. Clinical, biologic, and histologic features of late relapses in diffuse large cell lymphoma.
Cabanillas F; Velasquez WS; Hagemeister FB; McLaughlin P; Redman JR
Blood; 1992 Feb; 79(4):1024-8. PubMed ID: 1737086
[TBL] [Abstract][Full Text] [Related]
10. High-dose ifosfamide in combination with etoposide and epirubicin (IVE) in the treatment of relapsed/refractory Hodgkin's disease and non-Hodgkin's lymphoma: a report on toxicity and efficacy.
Proctor SJ; Taylor PR; Angus B; Wood K; Lennard AL; Lucraft H; Carey PJ; Stark A; Iqbal A; Haynes A; Russel N; Leonard RC; Culligan D; Conn J; Jackson GH
Eur J Haematol Suppl; 2001 Jul; 64():28-32. PubMed ID: 11486397
[TBL] [Abstract][Full Text] [Related]
11. 'Relative' chemotherapy sensitivity: the impact of number of salvage regimens prior to autologous stem cell transplant for relapsed and refractory aggressive non-Hodgkin's lymphoma.
Chen CI; Roitman D; Tsang R; Stewart AK; Keating A; Crump M
Bone Marrow Transplant; 2002 Dec; 30(12):885-91. PubMed ID: 12476281
[TBL] [Abstract][Full Text] [Related]
12. Testicular lymphoma: late relapses and poor outcome despite doxorubicin-based therapy.
Touroutoglou N; Dimopoulos MA; Younes A; Hess M; Pugh W; Cox J; Cabanillas F; Sarris AH
J Clin Oncol; 1995 Jun; 13(6):1361-7. PubMed ID: 7751880
[TBL] [Abstract][Full Text] [Related]
13. 90Y-Ibritumomab Tiuxetan consolidation after autologous stem cell transplantation improves survival of patients with intermediate-/high-risk diffuse large B-cell lymphoma not responding adequately to first-line treatment.
Mondello P; Pitini V; Arrigo C; Derenzini E; Mian M
Anticancer Res; 2014 Sep; 34(9):5121-5. PubMed ID: 25202102
[TBL] [Abstract][Full Text] [Related]
14. VACOP-B versus VACOP-B plus autologous bone marrow transplantation for advanced diffuse non-Hodgkin's lymphoma: results of a prospective randomized trial by the non-Hodgkin's Lymphoma Cooperative Study Group.
Santini G; Salvagno L; Leoni P; Chisesi T; De Souza C; Sertoli MR; Rubagotti A; Congiu AM; Centurioni R; Olivieri A; Tedeschi L; Vespignani M; Nati S; Soracco M; Porcellini A; Contu A; Guarnaccia C; Pescosta N; Majolino I; Spriano M; Vimercati R; Rossi E; Zambaldi G; Mangoni L; Rizzoli V
J Clin Oncol; 1998 Aug; 16(8):2796-802. PubMed ID: 9704732
[TBL] [Abstract][Full Text] [Related]
15. Autologous bone marrow transplantation for patients with relapsed or refractory diffuse aggressive non-Hodgkin's lymphoma: value of augmented preparative regimens--a Southwest Oncology Group trial.
Stiff PJ; Dahlberg S; Forman SJ; McCall AR; Horning SJ; Nademanee AP; Blume KG; LeBlanc M; Fisher RI
J Clin Oncol; 1998 Jan; 16(1):48-55. PubMed ID: 9440722
[TBL] [Abstract][Full Text] [Related]
16. Rituximab (anti-CD20 monoclonal antibody) therapy for progressive intermediate-grade non-Hodgkin's lymphoma after high-dose therapy and autologous peripheral stem cell transplantation.
Tsai D; Moore H; Hardy C; Porter D; Loh E; Vaughn D; Luger S; Schuster S; Stadtmauer E
Bone Marrow Transplant; 1999 Sep; 24(5):521-6. PubMed ID: 10482937
[TBL] [Abstract][Full Text] [Related]
17. Risk of relapse and clinico-pathological features in 103 patients with diffuse large-cell lymphoma in complete response after first-line treatment.
Sanz L; López-Guillermo A; Martínez C; Bosch F; Esteve J; Cobo F; Montoto S; Perales M; Bladé J; Cervantes F; Nomdedeu B; Campo E; Montserrat E
Eur J Haematol; 1998 Jul; 61(1):59-64. PubMed ID: 9688294
[TBL] [Abstract][Full Text] [Related]
18. Prognostic factors for treatment outcome in autotransplantation of intermediate-grade and high-grade non-Hodgkin's lymphoma with cyclophosphamide, carmustine, and etoposide.
Wheeler C; Strawderman M; Ayash L; Churchill WH; Bierer BE; Elias A; Gilliland DG; Antman K; Guinan EC; Eder JP
J Clin Oncol; 1993 Jun; 11(6):1085-91. PubMed ID: 8099120
[TBL] [Abstract][Full Text] [Related]
19. Is there any role for transplantation in the rituximab era for diffuse large B-cell lymphoma?
Gisselbrecht C
Hematology Am Soc Hematol Educ Program; 2012; 2012():410-6. PubMed ID: 23233612
[TBL] [Abstract][Full Text] [Related]
20. Low-grade lymphoma following intensive treatment of large-cell lymphoma.
Spector N; Pulcheri W; Nucci M; de Morais JC; de Oliveira HP
Acta Haematol; 1993; 90(1):48-51. PubMed ID: 8237275
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
